

Luminita Pricop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8578928/publications.pdf>

Version: 2024-02-01

14
papers

1,747
citations

1307594

7
h-index

1281871

11
g-index

14
all docs

14
docs citations

14
times ranked

1721
citing authors

#	ARTICLE	IF	CITATIONS
1	OA37â€fSecukinumab treatment in children and adolescents with enthesitis-related arthritis and juvenile psoriatic arthritis: efficacy and safety results from a Phase 3 study. <i>Rheumatology</i> , 2022, 61, .	1.9	0
2	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001845.	3.8	11
3	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2020, 47, 539-547.	2.0	16
4	P250â€fEffect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study. <i>Rheumatology</i> , 2020, 59, .	1.9	0
5	256â€fSecukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2019, 58, .	1.9	3
6	257â€fSecukinumab demonstrates a consistent safety profile with up to 5 yearsâ€™ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. <i>Rheumatology</i> , 2019, 58, .	1.9	1
7	263â€fSecukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. <i>Rheumatology</i> , 2019, 58, .	1.9	0
8	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naïve patients with psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 497-510.	1.4	15
9	Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2019, 6, 113-121.	0.6	5
10	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018, 20, 47.	3.5	117
11	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212687.	0.9	193
12	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1107-1123.	1.4	35
13	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015, 386, 1137-1146.	13.7	722
14	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015, 373, 1329-1339.	27.0	629